Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021 Biotech Investing
Johnson & Johnson Faces Class-Action Lawsuit Over Benzene-Tainted Neutrogena and Aveeno Sunscreen Products Medical Device Investing
KEYTRUDA® Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC Pharmaceutical Investing
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Johnson & Johnson Investigation Medical Device Investing
Johnson & Johnson Consumer Inc. Issues Voluntary Recall of Specific NEUTROGENA® and AVEENO® Aerosol Sunscreen Products Due to the Presence of Benzene Medical Device Investing
Lobe Sciences Appoints Gilberto Jesús Mendoza, President of the World Boxing Association, to Advisory Board Cannabis Investing News
Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research Biotech Investing
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes Medical Device Investing
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases Pharmaceutical Investing
